Clinical Trial Update: Safety Study of AMG 811 in Subjects With Systemic Lupus Erythematosus With and Without Glomerulonephritis [Phase 1]

View source ↗

Summary

Amgen's Phase 1 safety study of AMG 811 in subjects with systemic lupus erythematosus, with and without lupus nephritis, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• AMG 811

Snippet

Sponsor: Amgen | Conditions: Nephritis, Systemic Lupus Erythematosus | Phase 1 | Status: COMPLETED